MAP2K7 and metastatic melanoma: The novel MEK inihibitor trametinib, which we discovered by screening to detect p15-inducing agents [11], improved progression-free and overall survival in patients with BRAF V600E-mutated metastatic melanoma [6], and was approved by FDA in 2013.